Which hedge funds own URGN? UROGEN PHARMA LTD, Q2 2026 13F holders
Healthcare · Open on the interactive board
7 of the hedge funds tracked by WhaleCreep disclosed a position in URGN (UROGEN PHARMA LTD) in their Q2 2026 13F filings, worth $124.8m in total. The largest holder by portfolio weight is Point72 Asset Management LP at 0.1% of its book. 3 managers opened a new position this quarter: Point72 Asset Management LP, Polen Capital Management, Renaissance Technologies LLC. 1 exited: Farallon Capital Management.
7tracked managers holding
3opened this quarter
1exited this quarter
Which hedge funds hold URGN? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Point72 Asset Management LP | Q2 2026 | 0.1% | $56.1m | 1,525,549 | – | new |
| Woodline Partners | Q2 2026 | 0.1% | $18.4m | 500,726 | 0% | held |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $42.2m | 1,145,819 | 12% | added |
| Polen Capital Management | Q2 2026 | 0.0% | $1.1m | 29,615 | – | new |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $2.6m | 70,300 | – | new |
| Millennium Management | Q2 2026 | 0.0% | $3.9m | 106,692 | -71% | reduced |
| Citadel Advisors | Q2 2026 | 0.0% | $477.8k | 12,985 | -95% | reduced |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Farallon Capital Management | 0.0% | $197.8k |
How has hedge fund ownership of URGN changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 7 | $124.8m |
| Q1 2026 | 5 | $39.1m |
| Q4 2025 | 3 | $17.7m |
| Q3 2025 | 3 | $11.8m |
| Q2 2025 | 4 | $7.3m |
| Q1 2025 | 4 | $42.5m |
| Q4 2024 | 3 | $8.1m |
| Q3 2024 | 2 | $23.0m |
| Q2 2024 | 3 | $97.9m |
| Q1 2024 | 3 | $63.0m |
| Q4 2023 | 4 | $49.5m |
| Q3 2023 | 4 | $26.0m |
| Q2 2023 | 2 | $776.4k |
| Q1 2023 | 2 | $453.2k |
| Q4 2022 | 2 | $392.9k |
| Q3 2022 | 2 | $367.0k |
Counts every tracked manager that disclosed URGN in that quarter's filing, including managers that have since stopped filing.